Treeline Biosciences reports TEAD degraders

AI Briefing

• – Treeline Biosciences reports developing new proteolysis targeting chimera (PROTAC) compounds targeting TEAD in cancer treatment.
• – The company's approach combines an E3 ubiquitin ligase-binding moiety with a TEF-targeting moiety.
• – Potential therapeutic applications for the compounds are being explored.